Video

Urologists discuss why kidney stones should be considered “a mainstream public health problem”

Author(s):

Urology Times staff

“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.

Nevo is chief of endourology at University Hospitals Urology Institute and is an assistant professor of urology at Case Western Reserve University School of Medicine in Cleveland, Ohio. Shoag is a urologist at University Hospitals and an assistant professor of urology at Case Western Reserve University School of Medicine, Cleveland, Ohio.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman talking with doctor | Image Credit: © LuneVA/peopleimages.com - stock.adobe.com
Timothy D. Lyon, MD, answers a question during a video interview
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Related Content
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
Why kidney stones will become more prevalent over time
February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff
“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
Published ASPIRE data show noninferior stone-free rate with SURE vs URS
December 23rd 2024

Published ASPIRE data show noninferior stone-free rate with SURE vs URS

Hannah Clarke
The SURE procedure also demonstrated significantly better outcomes on the study’s secondary end points of stone clearance and residual stone volume.
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
FDA grants de novo clearance to Stone Clear device
November 13th 2024

FDA grants de novo clearance to Stone Clear device

Hannah Clarke
"The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake," says James E. Lingeman, MD.
FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1
September 4th 2024

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke
YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.
© 2025 MJH Life Sciences

All rights reserved.